U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459829) titled 'Study of CU06-1004 in Patients With Daibetic Macular Edema' on Feb. 26.
Brief Summary: This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 24 weeks. The study will have a 1:1:1 randomization (CU06-1004 200mg: CU06-1004 300mg: Placebo).
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
DME
Diabetic Macular Edema
Diabetic Macular Edema (DME)
Intervention:
DRUG: CU06-1004
CU06-1004 is an oral capsule. At room temperature, it appears as a white to off-wh...